Avoro Capital Advisors LLC Has $19.60 Million Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Avoro Capital Advisors LLC trimmed its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 36.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,250,000 shares of the company's stock after selling 1,291,505 shares during the period. Avoro Capital Advisors LLC owned about 2.89% of Kura Oncology worth $19,598,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Barclays PLC boosted its holdings in Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after acquiring an additional 84,563 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $436,000. Moody Aldrich Partners LLC lifted its holdings in shares of Kura Oncology by 42.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock worth $1,251,000 after purchasing an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after buying an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in Kura Oncology during the 4th quarter worth approximately $623,000.

Kura Oncology Stock Up 2.6 %

Shares of NASDAQ:KURA opened at $5.90 on Monday. The firm has a fifty day moving average of $7.07 and a 200 day moving average of $10.34. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $23.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market capitalization of $476.59 million, a PE ratio of -2.50 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on KURA. Wedbush restated an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a research note on Tuesday, April 8th. JMP Securities reissued a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. BTIG Research downgraded shares of Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. StockNews.com upgraded Kura Oncology from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Finally, UBS Group decreased their target price on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $25.50.

Insider Activity at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company's stock.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.